Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Using Machine Learning to assess Covid-19 risks

Srikanth Muthya, Renjith S Nair, Thanga Prabhu Arokiaswamy, Anusha Prakash
doi: https://doi.org/10.1101/2020.06.23.20137950
Srikanth Muthya
Cohere Med Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Srikanth.Muthya{at}gmail.com
Renjith S Nair
Cohere Med Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thanga Prabhu Arokiaswamy
Cohere Med Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anusha Prakash
Cohere Med Inc.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

IMPORTANCE Identifying potential Covid-19 patients in the general population is a huge challenge at the moment. Given the low availability of infected Covid-19 patients clinical data, it is challenging to understand and comprehend similar and complex patterns in these symptomatic patients. Laboratory testing for Covid19 antigen with RT-PCR | (Reverse Transcriptase) is not possible or economical for whole populations.

OBJECTIVE To develop a Covid risk stratifier model that classifies people into different risk cohorts, based on their symptoms and validate the same.

DESIGN Analysis of Covid cases across Wuhan and New York were done to identify the course of these cases prior to being symptomatic and being hospitalised for the infection. A dataset based on these statistics were generated and was then fed into an unsupervised learning algorithm to reveal patterns and identify similar groups of people in the population. Each of these cohorts were then classified and identified into three risk levels that were validated against the real world cases and studies.

SETTING The study is based on general population.

PARTICIPANTS The adult population were considered for the analysis, development and validation of the model

RESULTS Of 1 million observations generated, 20% of them exhibited Covid symptoms and patterns, and 80% of them belonged to the asymptomatic and non-infected group of people. Upon clustering, three clinically obvious clusters were obtained, out of which the Cluster A had 20% of the symptomatic cases that were classified into one cohort, the other two cohorts, Cluster B had people with no symptoms but with high number of comorbidities and Cluster C had people with few leading indicators for the infection with few comorbidities. This was then validated against 300 participants whose data we collected as a part of a research study through our Covid-research tool and about 92% of them were classified correctly.

CONCLUSION A model was developed and validated that classifies people into Covid risk categories based on their symptoms. This can be used to monitor and track cases that rapidly transition into being symptomatic which eventually get tested positive for the infection in order to initiate early medical interventions.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was self funded.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

We have followed all the ethical procedures and protocols to anonymise, store and handle the patient level data. This research was approved by the clinical and engineering advisory board at Cohere-Med Inc.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

This work used synthetic data generated from studies. For internal and external validation, open data sources were used.

https://www.kaggle.com/rupsikaushik/covid19-patientlevel-data

https://github.com/beoutbreakprepared/nCoV2019.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 25, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Using Machine Learning to assess Covid-19 risks
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Using Machine Learning to assess Covid-19 risks
Srikanth Muthya, Renjith S Nair, Thanga Prabhu Arokiaswamy, Anusha Prakash
medRxiv 2020.06.23.20137950; doi: https://doi.org/10.1101/2020.06.23.20137950
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Using Machine Learning to assess Covid-19 risks
Srikanth Muthya, Renjith S Nair, Thanga Prabhu Arokiaswamy, Anusha Prakash
medRxiv 2020.06.23.20137950; doi: https://doi.org/10.1101/2020.06.23.20137950

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)